

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 May 2024 (02.05.2024)



(10) International Publication Number
WO 2024/092219 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *C07D 207/448* (2006.01)

(21) International Application Number:
PCT/US2023/078062

(22) International Filing Date:
27 October 2023 (27.10.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/381,404 28 October 2022 (28.10.2022) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **CORTEZ, Guillermo S.**; c/o Eli Lilly and
Company, PO Box 6288, Indianapolis, Indiana 46206-6288
(US). **WANG, Yan**; c/o Eli Lilly and Company, PO Box
6288, Indianapolis, Indiana 46206-6288 (US). **ALAM, Ri-
azul**; c/o Eli Lilly and Company, PO Box 6288, Indianapo-
lis, Indiana 46206-6288 (US).

(74) Agent: **MCCRARY, Parker et al.**; Eli Lilly and Company,
P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: SELF-HYDROLYZING MALEIMIDES FOR BIOCONJUGATION

(57) Abstract: The present disclosure relates to novel compounds comprising self-hydrolyzing maleimide functional groups, salts of these compounds, pharmaceutically acceptable salts of these compounds, methods of making these compounds, and methods of using these compounds for bioconjugation to antibodies. The present disclosure also relates to antibody drug conjugates with improved stability under physiological conditions. The present disclosure also relates to antibody drug conjugates that include self-hydrolyzing maleimide functional groups.



WO 2024/092219 A1